Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$113.64 USD

113.64
6,318,358

+0.55 (0.49%)

Updated Sep 27, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis

by Zacks Equity Research

Lilly (LLY) enjoys strong fundamentals, which can help it withstand the short-term impact of the pandemic.

Benjamin Rains headshot

Pharma Giant Eli Lilly (LLY) Stock is a Buy During the Coronavirus Economy

by Benjamin Rains

Eli Lilly (LLY) stock closed the first quarter above where it started, which was no easy task. So let's dive into why investors might want to buy LLY stock right now...

Why Merck (MRK) is a Top Dividend Stock for Your Portfolio

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

AstraZeneca's Imfinzi Gets FDA Nod for SCLC Label Expansion

by Zacks Equity Research

AstraZeneca's (AZN) Imfinzi gets FDA approval as first-line treatment for extensive-stage small cell lung cancer patients. A phase III study on Farxiga in CKD patients meets endpoint earlier than expected.

Indrajit Bandyopadhyay headshot

Pharma, Biotech Players Step Up Efforts Against Coronavirus

by Indrajit Bandyopadhyay

Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $68.22, marking a -1.2% move from the previous day.

Eiger Completes NDA Submission of Progeria Drug Lonafarnib

by Zacks Equity Research

Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.

Lilly Gets CRL for Jardiance in Type I Diabetes Indication

by Zacks Equity Research

Lilly's (LLY) label expansion application seeking approval of its type II diabetes medicine as a treatment for type I diabetes fails to get approval from the FDA.

The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck

Kinjel Shah headshot

Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates

by Kinjel Shah

Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.

How Trading Your Own Retirement Can Fleece Your Financial Future - March 20, 2020

by Zacks Equity Research

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $70.86 in the latest trading session, marking a -1.07% move from the prior day.

Want To Retire Early? Learn the Intelligent Investing Secret - March 19, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Merck's Chronic Cough Candidate Achieves Goals in Phase III

by Zacks Equity Research

Merck's (MRK) two phase III studies on gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough meet the primary efficacy endpoints.

Kinjel Shah headshot

AstraZeneca/Merck's Lynparza Combo Ovarian Cancer Study Fails

by Kinjel Shah

AstraZeneca (AZN)/Merck's (MRK) study evaluating cediranib added to Lynparza fails to meet the primary endpoint of PFS in patients with platinum-sensitive relapsed ovarian cancer

Kinjel Shah headshot

Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates

by Kinjel Shah

Lilly (LLY) signs deal with AbCellera to co-develop antibody therapies to treat COVID-19. AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19.

Bristol Myers' Opdivo+Yervoy Combo Gets FDA Nod for HCC

by Zacks Equity Research

Bristol Myers (BMY) gets FDA approval for the Opdivo and Yervoy combination for the treatment of HCC.

Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4

by Zacks Equity Research

Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.

This is Why Merck (MRK) is a Great Dividend Stock

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Bristol-Myers Empliciti Combo Fails in First-Line Myeloma Study

by Zacks Equity Research

Bristol-Myers' (BMY) Empliciti, Revlimid and dexamethasone combination regimen fails to improve progression free survival in first-line multiple myeloma patients.

Simple Secrets Anyone Can Use to Reach Early Retirement - March 10, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Why Is Merck (MRK) Down 4.8% Since Last Earnings Report?

by Zacks Equity Research

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Idera Completes Recruitment in Late-Stage Melanoma Study

by Zacks Equity Research

Idera (IDRA) closes enrollment in the late-stage ILLUMINATE-301 study, evaluating the combo of tilsotolimod plus Yervoy in patients with anti-PD-1 refractory advanced melanoma.

Kinjel Shah headshot

Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates

by Kinjel Shah

Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.

Merck (MRK) Stock Moves -1.68%: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $81.58, marking a -1.68% move from the previous day.